Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Clinical Trials

17 clinical trials for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) — RECRUITING · PHASE1
• Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. — RECRUITING · PHASE1
• Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL — RECRUITING · PHASE1
• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT — RECRUITING · PHASE2
• EVALUATION OF SAFETY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH DASATINIB IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) — TERMINATED · PHASE2
• Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world — NOT_YET_RECRUITING
• A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE3
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL — COMPLETED · PHASE2
• A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL — COMPLETED · PHASE1
• Iclusig PMS in CML or Ph+ALL Patients — OTHER
• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) — COMPLETED · PHASE1
• Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium — COMPLETED
• CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey — COMPLETED
• Expanded Access Program of Ponatinib — OTHER
• Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. — TERMINATED · PHASE1
• Rollover Study of BMS-354825 in Patients With CML and Ph+ALL — COMPLETED · PHASE1

Refine this search